Our data showed that the tumor weight in the CCL3 treatment group was significantly higher than that in the PBS group, while the VIRMA knockdown group was not affected by CCL3 treatment, and the tumor weight was significantly lower than that in the control group (HuCCT1 + PBS: 0.81 ± 0.02 g, HuCCT1 + CCL3: 1.45 ± 0.08 g, HuCCT1-shNC + CCL3: 1.53 ± 0.04 g, and HuCCT1-shVIRMA + CCL3: 0.27 ± 0.02 g). Here, VIRMA is linked to neoplasm.